BPC-157 Multifunctionality Comment Paper in Pharmaceuticals: Angiogenesis and Nitric Oxide Pathway Discussion Continues Ahead of PCAC
A 2026 Pharmaceuticals (MDPI) comment paper responds to the Józwiak et al. 2025 multifunctionality review of BPC-157, focusing on the peptide's role in targeting angiogenesis and modulating nitric oxide's cytotoxic versus protective actions. The response paper argues BPC-157's clinical claim breadth — wound healing, GI ulcer repair, tendon healing, neuroprotection — derives from a single biochemical hub: the peptide's interaction with vascular endothelial growth factor receptor 2 (VEGFR2) signaling and the NO/cGMP axis. The discussion lands as BPC-157 sits on the FDA's bulks-list review track for the July 23-24 PCAC meeting, with the underlying mechanistic literature still anchored on a small number of research groups. The Pharmaceuticals exchange illustrates the pre-clinical evidence gap that PCAC will weigh against the wide compounding-pharmacy demand signal.